Australia and India strengthen links in health education and researchWed 22nd July 2015
Australia and India strengthen links in health education and research
One of Australia’s foremost cancer experts visited India from 6-11 July to deliver lectures at leading Indian hospitals, and academic and research institutions.
Dr Warwick Tong delivered lectures on attacking early metastisis, new models for cancer drug development and clinical trials, identifying opportunities for academic, research and industry collaborations with India. A video of Tong about his visit can be viewed here.
Dr Tong is a physician by training and CEO of Australia’s Cancer Therapeutics Cooperative Research Centres, which works at the cutting edge of medical research to develop new cancer drugs. He has 20 years of international experience as an executive manager in the pharmaceutical and biotechnology industry. He has held a range of leadership roles in drug development and business development across a number of therapeutic areas including oncology, metabolic and infectious disease.
While in India, he addressed students, academics and researchers at the following institutions:
i) All India Institute of Medical Sciences- New Delhi
ii) International Centre for Genetic Engineering and Biotechnology – New Delhi
iii) Rajiv Gandhi Cancer Institute and Research Centre- New Delhi
iv) Advanced Centre for Treatment Research and Education in Cancer - Mumbai
v) Adyar Cancer Centre - Chennai
vi) Apollo Cancer Institute – Chennai
vii) Basavatarakam Indo – American Cancer Hospital and Research Institute- Hyderabad
The visit took place under the Australia India Education Council’s (AIEC) Eminent Researcher Lecture Program. The AIEC is a bi-national body co-chaired by the Australian and Indian Education Ministers, for driving the Australia India education, training and research agenda.
Dr Tong expressed appreciation for the AIEC Eminent Researcher Lecture Program.
‘This AIEC initiative has provided an invaluable opportunity for me to engage with my Indian counterparts on how we can tackle the challenge of fighting cancer.’
He also held discussions with key industry stakeholders to explore opportunities for commercial collaboration.
